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Despite extensive research into factors that 
influence equity of access to nephrology 
care1–6, and the publication of several 
studies on a wide range of ethical issues 
that nephrologists confront in their daily 
practice7–29, limited clear and actionable 
guidance is available to clinicians on how 
to manage common and impactful ethical 
issues in nephrology. To address this 
problem, in 2018, the American Society of 
Nephrology (ASN), the European Renal  
Association–European Dialysis and 
Transplant Association (ERA- EDTA) 
and the International Society of Nephrology 
(ISN) formed a Joint Working Group 
on Ethical Issues in Nephrology. The 
group aims to highlight several important 
challenges of longstanding or emerging 
ethical concern for clinicians and to support 
the development of tools to guide ethical 
decision- making in clinical practice. Here, 
we address the first aim by describing ten 
challenges that have been identified by the 
Working Group as priorities for further 
accessing screening and preventive care for 
kidney disease in the absence of universal 
health coverage, issues in paediatric 
decision-making and conflicts of interest  
in pharmaceutical prescribing.
Ethical issues in healthcare commonly 
align with universal concerns about 
decision- making, fairness, prevention  
of harm and promotion of the wellbeing of  
individuals and communities. Such issues 
require unique considerations in the 
local context, and responses must engage 
with local ethical and social priorities, 
values, preferences and frameworks for 
decision- making. Key factors, such as 
whether public funding is provided for 
dialysis, have a substantial impact on ethical 
decision- making and priorities for ethical 
action within countries. Clinical ethics is 
often case- specific, and general principles 
and ideas must be applied according to the 
specifics and dynamics of each situation.
By promoting and facilitating inter-
national discussion and collaboration,  
the global professional community may 
reach an understanding of fundamental  
ethical values that underpin clinical practice  
and ensure that ethical considerations 
inform international collaborative research 
on issues in clinical practice and health  
policy. Accordingly, this article is intended 
neither to provide in- depth ethical analysis 
of the selected challenges nor to outline spe-
cific practical strategies or recommendations 
for resolution of ethical issues in particular 
contexts. The aim is to inspire further work, 
not only on the issues selected for action  
by the Working Group but also on other 
issues that may reflect urgent challenges for 
stakeholders in particular regions, countries 
or communities.
Equity in access to kidney failure care
Equity in health refers to the absence of 
inequalities or differences that are avoidable, 
unnecessary and unfair30. Inequalities of 
potential concern in kidney failure care 
may include differences not only in access 
to existing services but also in clinician 
training, regional standards of existing 
facilities and resources, and degree of 
government support31. Inequities in access 
to integrated kidney failure care, including 
ethical exploration and strive to motivate 
action on the second aim by explaining 
the potential value of ethical training and 
guidance tools to manage these issues.
The ten challenges comprise a range 
of interconnected issues that relate to 
improving global kidney health and the 
quality of life of people and communities 
affected by kidney disease (Box 1). They were 
identified by the Working Group through a 
process of discussion and consensus (Box 2). 
In this article, we focus on the role of health 
professionals in addressing these issues 
while acknowledging that engagement of 
other stakeholders, such as patients and 
policy- makers, and non- stakeholders such as 
ethicists and social scientists, in collaborative 
action, will be essential to support ethical 
policy and practice. Importantly, health 
professionals and other stakeholders face 
many additional challenges that are not 
discussed in this article, including problems, 
practices and policies that have important 
ethical implications, such as the costs of 
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dialysis, transplantation, and comprehensive 
conservative and supportive care, are 
widespread both between and within 
countries2,6,31. Clinicians who are responsible 
for managing limited healthcare resources 
may experience ethical anxiety if they are 
uncertain how to approach decision- making 
because of a lack of guidance, training or 
experience and/or moral distress if resource 
constraints limit their ability to provide 
appropriate care to those in need32,33.
Limited availability of kidney replace-
ment therapies (KRTs) and access to avail-
able resources are primarily influenced by 
socioeconomic realities rather than clinical 
factors. However, in some cases, race, gender 
or citizenship status may determine or 
strongly influence access4,5,34–36. Criteria 
used to allocate health resources are often 
intended to promote greater utility of out-
comes from the use of KRTs. Optimizing 
utility is usually interpreted as maximizing 
therapeutic gains (improvements in sur-
vival time and quality of life) from a given 
invest ment of resources. This approach may 
exacerbate health inequi ties by favouring 
patients who have less severe disease as a 
result of more privileged access to healthcare 
because treating patients who have a higher 
quality of life and/or are likely to live longer 
is often likely to have a greater therapeutic 
impact at a lower cost than treating patients 
who are sicker and/or likely to die sooner 
despite treatment (Fig. 1). Optimizing utility  
might therefore lead to a phenomenon 
known as ‘double jeopardy’37, in which  
the least privileged patients are further  
disadvantaged in resource allocation.
Although efforts to increase the 
availability of resources and to address 
barriers to access are essential in reducing 
inequities and improving health outcomes 
for all31, in the absence of sufficient 
resources, clinicians and policy- makers must 
strive to ensure that those that are available 
are allocated in such a way as to promote 
health equity. Determining frameworks 
for decision- making and criteria to guide 
allocation requires careful attention to the 
values and preferences of the populations 
among which resources will be allocated, 
and to the broader context of their social and 
healthcare systems and priorities1,14,22.
Ethical issues in the allocation of 
organs for transplantation have received 
considerable attention38, whereas equity 
of access to transplantation services has 
received far less scrutiny. The availability 
of a suitably matched kidney is essential 
to enable a patient with kidney failure to 
undergo transplantation, but many other 
factors underpin the inequities observed in 
rates of kidney transplantation at the local 
and international levels6,34–36. For example, 
when transplantation programmes are 
introduced, particularly in countries that 
lack universal health coverage, less affluent 
members of society are often excluded owing 
to financial barriers. This problem exists 
despite the fact that kidney transplantation 
and subsequent care are often less expensive 
than long- term dialysis. Financial barriers 
also exclude many patients from access to 
dialysis services. In 2010, >2 million people, 
mostly in low- and low- to- middle- income 
countries (LMICs), are estimated to have 
died as a result of lack of access to dialysis2. 
Even when the costs of dialysis care are 
substantially covered by insurance, related 
healthcare costs and social barriers to care 
may underlie a high rate of mortality in 
low- income populations39.
Health professionals have an important 
role in promoting equity of access to 
dialysis and transplantation services as 
well as to conservative and palliative care 
services. In particular, they can assist in 
reducing barriers to access by promoting 
the development of transplantation and 
dialysis services in public rather than private 
facilities; ensuring the development of 
equitable and transparent frameworks for 
allocation of organs from deceased donors 
and for rationing of dialysis resources when 
necessary; supporting timely discussion 
of and referral for transplantation or 
conservative care where available and 
appropriate; supporting patients to 
discuss opportunities for living donation 
with potential donors; and facilitating a 
dialogue between patients and their families 
about conservative or palliative care as an 
alternative to dialysis.
Ethical issues may arise when a 
nephrologist makes a clinical judgement  
that a patient would not benefit sufficiently 
from transplantation or dialysis to justify  
use of a donated kidney or dialysis services 
or to justify the burdens that are associated 
with these interventions. Such burdens 
include the physical and psychological 
impact of transplantation or dialysis on 
patients, such as fatigue, depression, adverse 
effects of medications and complications 
of treatment, as well as requirements for 
lifestyle modification such as dietary 
restrictions and disruption to normal 
routines owing to time- consuming and 
expensive ongoing medical care40. Family 
and informal caregivers of patients receiving 
KRTs may also experience some of these 
or related burdens as they strive to support 
patients financially, psychologically and 
socially41,42. A patient’s prognosis in terms  
of survival following transplantation or  
commencement of dialysis might 
be weighed against the economic costs 
of KRTs and the potential physical, 
psychological and social costs for patients 
and their families43,44. For some patients, 
particularly those with comorbidities such 
as dementia that substantially reduce their 
quality of life and/or ability to cope with the 
demands of transplantation or dialysis, KRTs 
might be expected to offer limited, if any, 
benefits in terms of survival gains or relief  
of symptoms of kidney failure40,43,45.
Clinical decision- making about 
suitability for KRTs may be subject to 
unrecognized social or cultural biases, for 
example, biases relating to patient age or 
ethnicity might influence the evaluation 
of risk factors for poor outcomes and 
underpin assumptions regarding the 
likelihood of non- adherence to treatment 
regimes in specific patient populations34,46. 
Decision- making may also be influenced by 
financial conflicts of interest, for example, 
if nephrologists or dialysis providers have 
a financial interest in retaining patients 
on dialysis rather than referring them for 
transplantation or conservative care1,7,47,48. 
These conflicts can occur when the design 
of healthcare systems and/or funding for 
dialysis and transplantation is such that 
nephrologists, nephrology units or hospitals 
can earn more by providing dialysis care to 
a patient than by providing post- transplant 
care. Such interests might also influence 
modality choice — for example, preference 
might be given to in- centre dialysis rather 
than home haemodialysis or peritoneal 
Box 1 | ethical challenges in nephrology
•	Achieving	equity	in	access	to	integrated	
kidney	failure	care
•	Setting	priorities	in	kidney	disease	
prevention	and	care
•	Supporting	shared	decision-	making	about	
kidney	failure	care
•	Avoiding	futile	or	overly	burdensome	
dialysis	treatment
•	Reducing	the	cost	of	dialysis	care	without	
compromising	quality
•	Preventing	organ	trafficking	and	‘transplant	
tourism’
•	Evaluating	the	risks	and	outcomes	of	living	
kidney	donation
•	Addressing	the	ethical	implications	of	
genetic	kidney	diseases
•	Managing	conflicts	of	interest	in	nephrology
•	Advocating	responsibly	for	kidney	health
Each	challenge	should	be	considered	in	the	
context	of	other	health	and	social	priorities	in	
individual	countries	and/or	societies.
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dialysis if a nephrologist has a financial 
interest in the centre or receives higher 
payments for providing in- centre care.
The development of practice guidelines, 
including ethical guidelines for allocation 
of resources when rationing is required, 
will support transparent, evidence- based 
decision- making regarding kidney failure 
care, help to reduce inequities in access to 
KRTs and reduce the risk of moral distress 
for physicians32,49,50.
Priority setting for kidney care
Priority setting for research in kidney 
disease has been explored previously51, 
but much work still needs to be done on 
priority setting for nephrology clinical 
practice22. Such prioritization is of particular 
concern for health policy- makers and health 
professionals in LMICs, where dialysis  
and/or transplantation programmes are 
being introduced that may entail long- term, 
potentially catastrophic costs to health 
systems and/or patients. Health authorities, 
policy- makers and the nephrology 
community must consider the implications 
of investing in kidney failure treatment, 
particularly high- cost KRTs such as 
haemodialysis, when such investment 
may occur at the expense of investment in 
treatment of other diseases that are greater 
public health priorities. In high- income 
countries, the introduction of high- cost, 
novel therapies may create similar dilemmas 
for policy- makers and/or insurance 
providers when deciding whether to 
subsidize these therapies, and for clinicians 
who support patients in choosing between 
treatment options.
Prevention of kidney disease is more 
cost- effective than the treatment of advanced 
kidney disease and its complications52. 
Nevertheless, investment in care of the 
relatively few patients who have kidney 
failure is often prioritized over prevention of 
the development and progression of chronic 
kidney disease in both high- income and 
lower- income countries31,53. Investments 
should be made in conservative and 
supportive care services for patients with 
chronic kidney disease and kidney failure as 
an alternative or complementary treatment 
to KRTs and also to provide care in settings 
where KRTs are not an option31,54. Where 
resources are limited, prioritizing prevention 
of kidney disease or conservative care may 
seem preferable to prioritizing KRTs for 
patients with kidney failure. This approach 
is likely to produce greater benefits overall 
for a larger number of people, satisfying 
utilitarian concerns that support a health- 
maximizing approach to resource allocation. 
Furthermore, investment in prevention 
is more likely than investment in KRTs 
to produce health benefits for the most 
disadvantaged populations, thus reducing 
inequities. However, investment in 
higher- cost services may offer additional 
benefits to communities, for example, by 
helping to prevent professional ‘brain drain’ 
and reducing medical travel abroad, thereby 
strengthening local health systems. On the 
other hand, such investment may promote 
development of a two- tier health system 
and create internal brain drain by attracting 
nephrologists to more expensive services 
that are more financially rewarding.
Maximizing utility should not be the 
only consideration in priority setting. 
Communities and individuals who are 
affected by priority decisions may have 
additional values and goals beyond utility 
gains, such as equity in opportunities for 
care, or may have preferences that include 
the provision of some opportunities for 
higher- cost care modalities. Furthermore, 
if investment in preventive care precludes 
provision of treatment for kidney failure, this 
restriction can create ethical dilemmas or 
distress for clinicians who encounter patients 
with kidney failure. Implementing policies 
that may result in denial of treatment to 
individuals is difficult for those who are 
trained to provide care as needed when 
a therapeutic relationship is established, 
especially if high- cost services such as 
haemodialysis are available to patients who 
can afford to pay for them.
Policy- makers and clinicians, together 
with patients and other stakeholders, may 
need to engage with a range of ethical 
dilemmas related to priority setting. 
Decisions regarding the prioritization of 
preventive, curative or palliative treatments 
or KRTs have implications for priority 
setting in workforce capacity building and 
training, as well as investment in clinical 
research and novel therapies. For example, 
training of nurses or allied healthcare 
fieldworkers may enable more effective 
provision of primary kidney care in 
lower- income countries55.
Shared decision- making
Shared decision- making requires clinicians to 
respect patient autonomy (that is, their right 
to self- governance) by treating them as equals 
and supporting them to make voluntary and 
informed decisions about their care through 
a process of dialogue that explores all options 
for treatment, including conservative or 
supportive care (Fig. 2). Although definitions 
and implementation models vary56, in many 
countries shared decision- making is now 
the standard conceptual approach to making 
clinical decisions. In nephrology, shared 
decision- making is particularly important 
when choosing KRTs or transitioning from 
dialysis to supportive care (Fig. 2). This 
approach is frequently recommended as  
a strategy to prevent conflicts in end-of- 
life care and to avoid futile treatment, 
parti cularly in the context of dialysis57,58. 
Shared decision-making is also a valuable 
tool to prevent coercion or manipulation 
of patients, which may result in unwanted 
treatment, for example, if nephrologists 
repeatedly question a patient’s decision to 
decline KRTs47.
Several potential barriers to use of 
shared decision- making exist. First, 
clinicians may be unfamiliar with this 
approach or may not be trained in its use. 
A 2015 study of American nephrology 
trainees highlighted gaps in self- reported 
preparedness to provide end- of- life care to 
Box 2 | Selection of the ethical challenges
The	American	Society	of	Nephrology,	the	European	Renal	Association–European	Dialysis	and	
Transplant	Association	and	the	International	Society	of	Nephrology	(ASN-	ERA-	EDTA-	ISN)	Joint	
Working	Group	on	Ethical	Issues	in	Nephrology	was	convened	by	the	leaderships	of	the	three	
societies.	The	members	include	societal	executive	officers,	nephrologists	who	have	served	on	
societal	ethics	committees	and	individuals	with	ethics	expertise.	This	membership	was	not	
intended	to	provide	a	global	demographic	representation	of	nephrologists	but	rather	to	draw		
on	the	knowledge	of	society	leaders	regarding	topical	ethical	issues	that	have	been	discussed	
informally	within	their	societies	over	the	past	few	years.
An	initial	review	of	the	literature	was	performed	to	identify	potential	issues	of	interest	pertaining	
to	dialysis,	transplantation	and	general	nephrology.	These	issues	were	further	considered	in	light		
of	discussions	held	during	an	ISN	summit	on	end-	stage	kidney	disease	(kidney	failure)	in	Sharjah,	
United	Arab	Emirates,	in	March	2017	(reF.31).	In	May	2018,	the	working	group	discussed	and	refined	
the	preliminary	list	of	potential	issues	and	selected	a	set	of	priority	ethical	challenges	by	consensus	
(Box 1).	These	topics	were	chosen	because	they	reflect	concerns	that	are	common	to	members	of	
the	three	societies	and	are	thus	priorities	for	collaborative	work.	Two	additional	topics	were	added	
following	feedback	from	reviewers	on	an	earlier	version	of	this	manuscript.	The	chosen	challenges	
comprise	a	range	of	interconnected	issues	that	relate	to	improving	global	kidney	health	and	the	
quality	of	life	of	people	and	communities	affected	by	kidney	disease.
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patients, including lack of familiarity with 
existing guidelines for shared decision- 
making59. Providing training is important 
to support communication about treatment 
options and end- of- life decision- making 
in ways that are culturally appropriate 
and informed by the realities of the local 
healthcare system and social context60–62.
Second, nephrologists may believe 
that discussions about end- of- life care, 
transplantation or dialysis modality choice 
are not a priority within the context 
of their professional role or should be 
referred or delegated to other healthcare 
professionals60,61. This barrier can be 
addressed through professional guidance to 
clarify responsibilities and by core speciality 
training aimed at developing the skills that 
are necessary to engage in such discussions 
effectively.
Third, some clinicians may believe 
that discussion of all treatment options 
for kidney failure may cause unjustifiable 
harm to some patients and their families; 
for example, if they are concerned that 
promoting living donation may expose 
potential donors to harm, if they believe 
that discussing transplantation when there 
is a low probability of a patient receiving 
a transplant may cause distress, or if they 
believe that the financial burdens of dialysis 
may be catastrophic for a patient and their 
family22,63. Perceived conflicts between 
physician duties of non- maleficence 
and respect for patient autonomy may 
lead to paternalistic practices with 
harmful consequences. Failure to disclose 
information to patients and their families 
about options for care (and their risks and 
benefits) that are within the reach of local 
possibilities shows a lack of respect for the 
autonomy of patients and their families, 
and disempowers them from advocating 
to address barriers to care. This failure may 
also lead to poorer decision- making, and 
undermine trust in therapeutic relationships, 
particularly as such information may be 
discovered through other means64. Health 
professionals working in environments 
in which treatment options are limited 
should carefully consider the implications 
of discussing or withholding information 
regarding treatment options that may be 
locally unavailable.
Avoiding futile dialysis
The avoidance of futile treatment — that 
is, treatment that will not achieve its goal 
or for which the disadvantages exceed the 
benefits in an individual patient — is a 
widely accepted principle in medicine. In 
practice, however, determining when an 
intervention is likely to be futile is ethically 
and clinically complex. Patients, their 
families and clinicians may disagree on 
the goals of treatment, the probability of 
achieving these goals, the clinical course 
of these goals, and the threshold for success 
at which futility may be defined. Conflicts 
may exist between the values, beliefs and 
preferences of clinicians versus those of 
patients and/or their families, particularly 
One young, otherwise healthy patient 
receiving haemodialysis at home for 
12 h per week
One person in good health able to enjoy all 
activities of daily living and contribute to 
society through work for several years
a Option A Outcome A
Patient with kidney failure who has 
reliable access to dialysis, 
immunosuppression and follow-up care
Transplant recipient in good 
health with good expected 
survival and quality of life
Option A Outcome A
Patient with kidney failure who lives in a remote 
area with no dialysis service and has unreliable 
income, access to medication and follow-up care
Transplant recipient at high risk 
of graft failure and mortality in 
the event of complications
Option B Outcome B
Elderly patient with multiple comorbidities
who requires thrice-weekly in-hospital 
dialysis sessions of 4 h (total of 12 h)
One person in poor health who is able to enjoy 
few activities of daily living, is dependent on 
others for care and has a limited life expectancy
b
Option B Outcome B
Fig. 1 | optimizing the utility of treatment outcomes in kidney failure can exacerbate health 
inequalities. a | Allocation of haemodialysis tends to favour younger, healthier patients for whom 
treatment offers a better return on investment by optimizing health outcomes. Providing 12 h of 
in- hospital haemodialysis per week to an elderly patient with multiple comorbidities produces less 
utility (measured in terms of survival time, health status and quality of life) than providing 12 h 
of haemo dialysis in the home for a young, otherwise healthy patient with kidney failure. Providing 
haemo dialysis for the elderly patient is also likely to be the more costly option as they will require 
treatment for their comorbidities and might be more likely to experience complications. b | Health- 
maximizing approaches to the allocation of kidney transplant resources may favour patients who have 
more privileged access to healthcare as they are more likely to have good outcomes from transplan-
tation (measured in terms of graft and patient survival) than patients who face barriers in accessing 
healthcare. In this case, the disadvantage experienced by patients who lack access to dialysis is 
particularly severe because if they are denied transplantation they will likely die from kidney failure.
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within multicultural societies. Incorrect 
assumptions that a judgement of futility with 
regard to one intervention (such as dialysis) 
may preclude alternative treatments (such 
as comprehensive conservative care) or lead 
to the abandonment of care also complicate 
discussions of futility.
Although it may be straightforward to 
determine whether dialysis will be effective 
in performing specific biochemical clearance 
functions, such as partially correcting 
metabolic and homeostatic derangements in 
a patient with kidney failure, estimating their 
clinical prognosis and determining whether 
the initiation or continuation of dialysis will 
support their broader life goals may be more 
difficult65. For some patients, the potential 
benefits of dialysis may be outweighed by 
harms such as those that are associated with 
‘medicalization’ of the end- of- life period, 
prolongation of a life that they judge to be 
not worth living or with a brief extension of 
life at a catastrophic financial cost to their 
family40,66. The provision of futile dialysis is 
not only harmful to patients but may also 
cause distress to their families and health 
professionals and impose a substantial 
burden on health systems67.
More tools to support shared decision- 
making about dialysis, such as evidence- 
based decision- making tools54,68 and 
guidelines developed by national or regional 
nephrology societies62,69–71, as well as efforts 
to disseminate, facilitate and encourage the 
use of these tools, are needed. The use of 
such tools would support a more inclusive 
approach to shared decision- making in 
which health professionals, patients and 
their families can define the goals of care, 
engage with objective clinical evidence, 
formulate a shared understanding of the 
risks and benefits of the available treatment 
options (including a time- limited trial of 
dialysis) and have the ability to revoke or 
modify a previous decision67. Tools and 
training to support shared decision- making 
should also engage with relevant legal 
frameworks (such as those that determine 
legally authorized surrogate decision- makers 
for patients who lack decision- making 
capacity) and with tools to help facilitate 
resolution of conflict when fundamental 
disagreement exists between stakeholders 
as to the appropriate use of life- sustaining 
interventions. Knowledge of relevant 
legislative frameworks, for example, 
may help to ensure that physicians and 
surrogate decision- makers are confident 
in advocating for treatment or treatment 
cessation options that they judge to be 
ethically appropriate, without fear of 
litigation or criminal prosecution. The 
establishment of a systematic process for 
review and resolution of conflicts regarding 
the potential futility of an intervention,  
or other aspects of clinical decision- making, 
may be helpful in managing ethical 
disagreements72.
Decision- making about the potential 
benefits and risks of treatment options 
for individual patients must be carefully 
distinguished from decision- making about 
resource allocation. Resource allocation 
guidelines should exclude the provision 
of futile treatments to avoid wasting 
healthcare resources. In cases where 
treatment is not considered to be futile,  
but rationing of relevant resources for 
treatment is unavoidable, patients may  
be denied access to a particular treatment 
if their need is not considered a priority 
according to ethically justified resource 
Clinical considerations
• Kidney failure diagnosis
• Comorbidities
• Frailty and/or 
function status
• Projected prognosis
System-level considerations
• KRT availability
• Supportive care availability
• Government policies
• Funding and/or 
reimbursement
Patient considerations
• Values and culture 
• Lived experience
• Life goals
• Information needs
• Quality of life
• Family resources and values
a
b
Physician information
and recommendations
Diagnosis
of kidney
failure
Patient (+/– family)
preferences and decisions
Societal values and preferences
Conservative care
Haemodialysis
Peritoneal dialysis
Kidney transplantation
Shared decision-
making
Shared
decision-
making
Trust Time
Cultural
competency
Communication
Empathy
Fig. 2 | Navigating pathways for treatment of kidney failure requires shared decision-making. 
a | Considerations for shared decision- making in the context of kidney failure. b | Several decision- 
making moments may occur following a diagnosis of kidney failure. Patients may have a range of treat-
ment options to select from, and may be required to re- evaluate their decisions in the light of resource 
constraints, treatment outcomes or opportunities for treatment, e.g. transplantation. Shared decision- 
making is a valuable process for patients, their families and physicians, even when treatment options 
may be limited. KRT, kidney replacement therapy.
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allocation criteria. The number of people 
in need of an intervention, and the 
potential benefits of treatment if it were 
available, should nevertheless be assessed 
and documented, and information regarding 
such cases should be reported to appropriate 
registries to inform and motivate efforts to 
improve the availability of resources.
Reducing the cost of dialysis
Efforts to reduce the costs of dialysis care 
are especially important in contexts where 
costs frequently preclude access. In Asia and 
Africa, for example, the majority of people 
with kidney failure cannot afford dialysis2. 
Health policy- makers and insurance 
providers may establish policies aimed at 
reducing the costs of care that may pose 
little threat to patient outcomes or quality of 
care, for example, by prioritizing peritoneal 
dialysis over haemodialysis73. However, 
some strategies that may reduce costs or 
enable more patients to access dialysis, such 
as reducing the duration and/or frequency of 
dialysis sessions, may have a negative impact 
on outcomes and thus pose ethical dilemmas 
for clinicians involved in decision- making. 
Conversely, efforts to improve the quality 
of care for some patients may reduce access 
for others. For example, in the context of 
limited availability, providing dialysis three 
times a week, as is standard in high- income 
countries, rather than twice a week, may 
reduce the number of patients who can 
access treatment74.
Large, centrally located dialysis centres 
with consolidated expertise may provide 
better outcomes than smaller clinics75,76. 
In the context of peritoneal dialysis, such an 
advantage might in part be due to a positive 
association between provider support for 
this dialysis modality, patient volume and 
outcomes. Although smaller clinics might 
potentially be better able to tailor care to 
the needs of individual patients, healthcare 
providers in such clinics might collectively 
have less experience or expertise, for 
example, in managing particularly complex 
cases or rare complications. Smaller clinics 
might also have less ready access to broader 
healthcare expertise or specific healthcare 
resources, if clinic size is proportionate to 
that of local healthcare infrastructure or 
economies of scale preclude investment 
in the specific resources. However, the 
latter may provide greater access to care 
for patients living in remote areas.
The relationships, behaviours and 
decisions of multiple stakeholders may 
substantially influence the costs of resources 
required for the provision of dialysis and 
the financial returns that are available for 
individuals and institutions. Stakeholders 
and potential financial beneficiaries may 
include governments, healthcare providers 
and professionals, manufacturers of 
dialysis system components and drugs, and 
transport companies. For example, the cost 
of dialysis system components may be more 
readily controlled by health authorities when 
these are manufactured within the country, 
and the costs of providing dialysis care 
within a country may be partially offset by 
the benefits of the local dialysis economy, 
including taxes paid by service providers and 
consumers and the creation of local jobs. 
On the other hand, perverse incentives may 
encourage disproportionate expenditure on 
dialysis, for example, if nephrologists are 
paid high fees for providing dialysis care that 
may encourage over- servicing or discourage 
referral of patients for transplantation or 
conservative care. By contrast, in the context 
of a fixed payment for dialysis, there is a risk 
that cost- saving measures may compromise 
the quality of care in order to maximize 
profits, for example, by allotting the same 
budget to an increased patient volume 
so that the consultation time per patient 
is reduced.
Ethical analysis may assist clinicians, 
policy- makers and community stakeholders 
in managing potential conflicts of interest 
and making decisions that will promote 
better care and patient outcomes without 
creating or exacerbating inequities of 
access or quality of care. In addition, ethical 
guidance is needed to ensure that the fear 
of compromising quality of care does not 
lead to avoidance of care altogether. In some 
contexts, compromises may be necessary; 
clinical standards that are considered best 
practice and outcomes for dialysis care in 
some countries or communities may not 
be an appropriate measure of success in 
others, particularly when compared in the 
context of broader social and healthcare 
goals and standards. Moreover, standards 
that are deemed appropriate at one point in 
time might be later challenged based on new 
evidence. The nephrology community must 
strive to promote less expensive therapeutic 
options and to advocate for the research 
and development of affordable treatment 
modalities. Finally, ethical guidance may be 
needed to support decision- making when 
tensions arise between different ethical 
concerns. For example, if all patients want 
higher- quality care but only some are able 
to pay for such care, patient autonomy and 
concern for health equity are in tension. 
Furthermore, if informing patients of 
compromises in care may cause anxiety, 
distress or avoidance of care, then respect 
for autonomy and duties of beneficence and 
non- maleficence are in tension.
Organ trafficking
As many as 10% of kidney transplantations 
performed worldwide each year are 
estimated to involve organ trafficking, 
in which organs are treated as a saleable 
commodity, or transplant tourism, in which 
patients travel internationally to purchase 
a kidney in circumstances that involve 
organ trafficking or undermine national 
self- sufficiency in transplantation in the 
destination country77. These practices cause 
great harm to vulnerable people who are 
forced to sell their kidneys as well as to 
their families and communities78–80, and 
also endanger the transplant recipients81–83. 
Furthermore, organ trafficking and 
transplant tourism have fuelled unethical 
practices, such as the execution of prisoners 
for organ procurement and sale in China, 
and the prioritization of wealthy foreign 
patients in the allocation of deceased donor 
organs84,85.
Organ trafficking, particularly the 
procurement and use of organs from 
prisoners or individuals who are coerced into 
providing their organs86, undermines trust 
in legitimate donation and transplantation 
programmes, and exacerbates inequities 
in donation and transplantation. Although 
ethical guidance is available at the level 
of broad principles established by the 
international community through the World 
Health Organization87 and the Declaration 
of Istanbul Custodian Group86,88, health 
professionals must contend with several 
complex ethical issues if they are to assist 
in preventing organ trafficking89. Ethical 
dilemmas may arise for nephrologists in 
managing patients who plan to travel abroad 
for an illegal transplant, who return from 
abroad after receiving a transplant that  
they suspect to have been trafficked or  
who they suspect to be involved in domestic 
organ trafficking90–93. These dilemmas often 
involve tensions between duties of care to 
patients and obligations to prevent harm 
to others. For example, refusal to facilitate 
travel abroad for transplantation when 
organ trafficking is suspected, for example, 
by declining to perform clinical investigations 
requested by the destination transplant 
centre, may delay or prevent patients from 
obtaining a transplant. Although such refusal 
is consistent with duties to prevent harm 
to the patient, given the clinical, financial 
and legal risks associated with travel for 
commercial transplantation, in many cases 
the overriding ethical justification may be the 
duty to prevent harm to others.
www.nature.com/nrneph
P e r s P e c t i v e s
Ethical dilemmas also arise when 
reporting cases of suspected organ trafficking 
to inform actions against health professionals 
or others involved in transplant- related 
crimes may involve a breach of patient 
confidentiality91,92. More work is needed 
to support management of ethical issues 
relating to trafficking or tourism in the 
local context, for example, by establishing 
policy or legislation to govern and facilitate 
reporting of suspected cases of organ 
trafficking in a manner that protects 
patient privacy and vulnerable people 
who are forced to sell their kidneys, while 
enabling collection of data that may inform 
efforts to combat trafficking91,92. Health 
professionals may also assist in preventing 
organ trafficking and transplant tourism 
by providing education and counselling to 
patients who may be considering travelling 
abroad to purchase a kidney86,89.
Risks of living kidney donation
A growing body of evidence regarding the 
long- term physical risks of living kidney 
donation within specific populations 
has enabled better risk assessment 
and in theory improved the quality of 
informed decision- making about living 
donation94. However, tools for evaluating 
and communicating risk to potential 
donors that have been developed for and 
informed by research in specific donor 
populations might be less relevant to 
other populations25,95. Emerging information 
about the psychosocial outcomes of donors 
and those who are declined as donors is 
also contributing to risk assessment and 
informed decision- making worldwide94–96.
Living donors may risk financial injury 
as a result of taking unpaid leave to donate 
or if they experience a complication from 
the nephrectomy that impairs their ability 
to return to work. They may also incur costs 
relating to medical care required for the 
purpose of donation or long- term follow- up 
care after donation97, as well as potential 
increases in premiums for health or life 
insurance or denial of insurance coverage94. 
Although infrequent, donors may experi-
ence psychosocial harm in the form of guilt, 
anxiety, depression or damage to relation-
ships with transplant recipients or family 
members, for example, if the transplant is 
not successful or expectations relating to 
the post- transplantation relationship are not 
met98,99. Furthermore, prospective donors 
who are declined or decide not to proceed 
with donation may experience psychosocial 
harm in the form of anxiety, guilt or distress, 
particularly if their intended recipient is 
unable to obtain a transplant100–102.
Clinicians and patients may experience 
difficulty in communicating and 
understanding the risks of donation, for 
example, when distinguishing between 
relative and absolute risks and when 
recognizing risks that are modifiable. 
Tools used to improve communication 
about risks in other healthcare fields such 
as oncology may help to support informed 
decision- making about donation103. 
Clinicians must contend with the ethical 
dilemma of determining when the risks 
are sufficiently great to justify refusing 
a willing donor25,102. Tensions may arise 
between respecting the autonomy of a 
prospective donor, supporting donation as 
a means of benefiting a person in need of 
transplantation and preventing avoidable 
harm to the donor. Such tensions may cause 
considerable ethical anxiety for clinicians, 
especially when the transplant candidate 
has limited chances of finding an alternative 
living donor or receiving a deceased donor 
kidney104.
Despite the available evidence, tailoring 
risk management to individual prospective 
living donors remains a highly subjective 
process bound by considerable uncertainty, 
particularly in LMICs, in which access 
to allied health professionals and other 
resources to support the evaluation of 
psycho social aspects of living donation may 
be limited. Nephrologists with responsibility 
for assessing prospective donors may lack 
expertise and experience in performing 
psychosocial evaluations and/or may have 
limited time to conduct such evaluations.  
It is particularly challenging to evaluate 
risks and consider these in the context of the 
potential benefits of successful transplan-
tation to both the recipient and the donor, 
while respecting the important role of the 
donor in judging the proportionality of 
those risks and benefits105. More ethical 
guid ance tools should be developed to  
assist in reducing ethical uncertainty 
and distress in contexts where clinical 
decision- making is not self- evident106,107.
Genetic kidney diseases
Emerging information about the role of 
genetic and epigenetic factors in kidney 
disease108 will expand the range of ethical 
issues confronting clinicians and patients. 
As is the case with genomics in medicine in 
general, increased use of genetic information 
in the investigation and management of 
kidney disease has potential benefits for 
patient autonomy and health, but also 
associated risks108. For example, use of 
genetic testing and genetic information 
may endanger patient privacy and 
confidentiality, and has the potential to 
cause harm to individuals, families and 
communities, for example, by increasing 
insurance premiums, creating social stigma 
or facilitating discrimination in employment. 
When a person is diagnosed with kidney 
disease, information about the aetiology 
of their condition may be relevant to their 
genetic relatives. Ethical issues may arise 
relating to obligations to disclose such 
information109 and/or to protect individuals 
from unwanted information about their 
genetic risk of disease110. The ethical duties 
of the nephrologist in supporting disclosure 
may be unclear111. Issues may also arise 
in the context of decision- making about 
procreation by an affected individual or 
couple112. Greater understanding of the 
genetic and epigenetic factors that influence 
kidney disease is also having an impact 
on treatment decision- making113 and risk 
assessment, including for potential living 
kidney donors who wish to donate to a 
genetic relative114.
In LMICs, unavailability of tools for 
genetic diagnosis and/or counselling may 
undermine the quality of care available for 
patients and increase inequities in access 
to care. The inability to identify a genetic 
cause of disease may lead to inappropriate 
treatment and the waste of scarce resources 
that could have been avoided with improved 
diagnosis of disease aetiology. To ensure that 
patients have access to appropriate care and 
are supported to make informed decisions 
about their care and the management of 
their genetic information, nephrologists 
require training and continuing education 
in this field, not only from a clinical and 
scientific perspective but also with regard 
to the ethical implications of genetic 
kidney diseases. Nephrologists should also 
advocate on behalf of patients for access 
to resources such as genetic testing and 
counselling services.
Managing conflicts of interest
As noted above, conflicts of interest on 
the part of various stakeholders, including 
health professionals and patient and 
advocacy organizations, may influence 
decision- making and undermine care and 
equity of access to care in the context of 
kidney disease. In particular, individual 
and organizational financial interests 
may influence the goals and priorities of 
patients, clinicians, healthcare providers 
and policy- makers and require careful 
management. The financial impact of 
kidney disease on societies, healthcare 
systems, patients and their families is 
substantial115–117. Reluctance to explicitly 
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acknowledge and engage with financial 
interests when setting goals of care or 
policy not only undermines transparency 
but may also have harmful consequences. 
For example, disproportionate investment 
in dialysis without comparable development 
of transplantation services and preventive 
kidney health programmes may hamper 
efforts to implement sustainable solutions  
to the problem of kidney disease.
Conflicts of interest can also have an 
impact on the development of clinical 
practice guidelines, for example, if financial 
interests on the part of companies sponsoring 
guideline development or individuals 
contributing to guideline development 
influence judgements regarding clinical  
best practice118–120. Strategies to prevent such 
an impact include mandatory requirements 
for the declaration of potential conflicts, 
recusal of individuals from involvement  
in decision- making when a conflict of 
interest exists and mandatory disclosure  
of unavoidable, potential or perceived 
conflicts of interest when guidelines are 
published.
Management of conflicts of interest 
requires clear processes and policies for 
use in particular contexts and specific 
attention to broader contextual factors 
that may underpin such interests or make 
their avoidance difficult. For example, 
the financial interests of physicians may 
be embedded in the structure of health 
payment systems such that their influence 
on clinical decision- making is readily 
overlooked.
Further work on the ethical implications 
of conflicts of interest in nephrology 
is needed, particularly with respect to 
determining situations in which such 
conflicts should preclude participation by 
individuals or organizations in decision- 
making118. Popular management strategies 
such as disclosure of conflicts are of limited 
efficacy120, and do not address the inherent 
ethical concerns regarding the impact of bias 
in decision- making, clinical judgement or 
scientific analysis. In addition, exploration 
of potential conflicts of interest within 
families who need to make decisions 
regarding treatment of kidney failure,  
as well as management strategies to address 
these conflicts, would be helpful. For 
example, clinicians may face difficulty 
when caring for prospective living related  
donors who may be emotionally and/or 
financially dependent on prospective 
transplant recipients and with families 
for whom decisions about initiation or 
cessation of dialysis may have significant 
financial consequences.
Responsible advocacy
Advocacy by health professionals in collab-
oration with patient organizations and  
individuals is vital to promote awareness  
and understanding of kidney health. In some 
contexts, advocacy may also be influential in 
gaining funding for research or care services 
from government, industry or philanthropic 
sources. Several ethical issues may arise in 
the context of advocacy efforts for kidney 
health. To date, no research has explored 
ethical issues of advocacy in this specific 
context.
First, growing awareness exists of 
ethical concerns regarding conflicts 
of interest in relationships between industry, 
professional medical societies and patient 
advocacy organizations121,122. The need to 
foster and maintain positive relationships 
with potential funding sources that are 
necessary to support vital research, training 
or community engagement activities may 
discourage kidney health advocates from 
speaking out on specific topics or issues in 
which funders may have a vested interest.
Second, factors that may influence the 
efficacy of advocacy efforts and fundraising 
appeals may also influence decision- making 
by organizations regarding which diseases, 
populations or therapies to prioritize for 
advocacy, potentially creating or sustaining 
inequities in kidney care. Such factors may 
include a lack of evidence or knowledge 
regarding the impact of particular diseases 
in specific populations, costs of care, stigma, 
political bias and perceived severity of need 
for care in a particular population123–125.
Third, physicians, patient organizations 
and other groups may intentionally or 
unintentionally exploit vulnerable patients 
or communities in advocacy efforts. Use of 
personal narratives is an established method 
of soliciting public donations to charities 
and promoting kidney donation126,127. 
Problematic practices in kidney health 
advocacy may include soliciting financial 
donations from wealthy patients and asking 
patients, their families or communities to 
publicly share stories of personal tragedy 
or disease that may be helpful in raising 
awareness or attracting funding128,129. 
The representation of individuals or 
communities in advocacy materials may 
expose them to stigmatization or violate 
their privacy if they feel unable to decline. 
Ensuring that therapeutic relationships are 
not exploited in this way and protecting 
individuals who may be unable to choose 
autonomously whether to participate 
in advocacy efforts, such as children, is 
essential. Establishing ethical guidelines 
to govern advocacy efforts would help to 
address such concerns, for example, by 
setting standards for transparency, consent 
and management of conflicts of interest.
Conclusions and a call to action
Each of the challenges described above 
comprises a range of complex issues that may 
have specific implications in the context of 
particular populations or healthcare systems. 
Each of these complex issues requires 
in- depth analysis by expert groups in order 
to understand the factors that underpin 
them and the ethical concerns that they may 
present in specific contexts. Collaborative 
action by nephrology communities, 
including stakeholders such as policy- 
makers and patients, is needed to develop 
tools, training modules and other resources 
to guide decision- making and support 
ethical practice. The ASN- ERA- EDTA- ISN 
Joint Working Group on Ethical Issues in 
Nephrology will encourage members of the 
three societies and partner organizations 
to initiate in- depth discussions about 
these issues with the aims of supporting 
Box 3 | Working group on ethical issues in Nephrology action plan
Form working groups to address the ten challenges
Convene	multidisciplinary,	multinational	working	groups,	including	patient	stakeholders,	who	will	
be	responsible	for	ongoing	work	on	each	challenge.	This	work	will	involve	the	exploration	of	issues	
and	the	development	of	tools,	including	educational	resources.
Develop a global multidisciplinary network and resource bank in nephrology ethics
Establish	an	e-	mail	list	and	website	to	facilitate	networking,	for	example,	by	providing	a	source		
of	information	to	assist	people	and	organizations	to	find	collaborators	with	relevant	expertise,		
and	to	communicate	information	about	opportunities	for	collaboration.	The	website	will	host	a	
curated	set	of	relevant	resources	including	ethical	analyses	of	specific	issues,	guidelines	and	
educational	tools.
Establish dedicated streams for nephrology ethics at society conferences
Dedicated	space	for	discussion	of	ethical	topics	will	be	established	in	society	conference	
programmes	to	give	greater	prominence	to	existing	work	on	ethics	in	kidney	health,	highlight		
the	importance	of	ethics	to	health	professionals	and	facilitate	the	development	of	collaborations	
to	investigate	current	and	emerging	ethical	issues	in	nephrology.
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the development of tools to guide ethical 
decision- making in clinical practice, 
adapting these tools to local contexts, 
building capacity amongst nephrologists to 
recognize and respond to ethical challenges, 
and making routine the application of these 
tools and principles to health policy, clinical 
practice and research (Box 3).
We call on health professionals, members 
of patient communities, policy- makers, 
ethicists, health economists and social 
scientists to take action in exploring and 
addressing ethical issues in nephrology 
that are of concern in their local context. 
Although ethical considerations in research 
and clinical decision- making are often  
noted in passing, we believe that giving a 
more prominent place to engagement with 
ethical issues is necessary. The ASN-ERA- 
EDTA- ISN Joint Working Group is eager to 
establish a sustainable programme of work 
that will enable regular review of issues and 
resources that may require updating in the 
light of emerging evidence or contextual 
changes that influence the manifestation 
and management of ethical issues. The 
societies are also committed to working 
in collaboration with other regional and 
national societies of nephrology, in order 
to draw on the wealth of global expertise 
and experience, and to ensure that the 
needs, values and preferences of the global 
community inform the development of a 
global bank of resources supporting ethical 
practice in kidney health.
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